[Two new very promising antithrombotic agents: pentasaccharide and ximelagatran].
The main anticoagulants presently used have several drawbacks. Two new compounds (pentasaccharide and ximelagatran) have shown in recent studies several interesting properties and results. Both are of non animal origin, do not induce thrombocytopenia and do not require laboratory controls. Pentasaccharide has a better efficacy than low molecular weight heparin in major orthopaedic interventions; it will be registered soon in several countries. Ximelagatran, which can be given orally and is in phase III investigation, could replace vitamin K antagonist in the future.
Regazzoni
Stefano
S
Dipartimento di medicina, Ospedale regionale di Lugano, Tessin. regazzonis@bluewin.ch
de Moerloose
Philippe
P
D001384:Azetidines / Q000627:therapeutic use*; D001596:Benzylamines; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D000077425:Fondaparinux; D006801:Humans; D011134:Polysaccharides / Q000627:therapeutic use*
D001384:Azetidines; D001596:Benzylamines; D005343:Fibrinolytic Agents; D011134:Polysaccharides; C426686:ximelagatran; D000077425:Fondaparinux